LT2707003T - Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai - Google Patents

Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai

Info

Publication number
LT2707003T
LT2707003T LTEP12782600.6T LT12782600T LT2707003T LT 2707003 T LT2707003 T LT 2707003T LT 12782600 T LT12782600 T LT 12782600T LT 2707003 T LT2707003 T LT 2707003T
Authority
LT
Lithuania
Prior art keywords
methyl
naphthacene
tetrahydroxy
octahydro
dioxo
Prior art date
Application number
LTEP12782600.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Catherine COULTER
Sean Johnston
Farzaneh Seyedi
Original Assignee
Paratek Pharmaceuticals, Inc.
Allergan Pharmaceuticals International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals, Inc., Allergan Pharmaceuticals International Limited filed Critical Paratek Pharmaceuticals, Inc.
Publication of LT2707003T publication Critical patent/LT2707003T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP12782600.6T 2011-05-12 2012-05-14 Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai LT2707003T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485179P 2011-05-12 2011-05-12
PCT/US2012/037838 WO2012155146A1 (en) 2011-05-12 2012-05-14 Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same

Publications (1)

Publication Number Publication Date
LT2707003T true LT2707003T (lt) 2019-10-10

Family

ID=47139728

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12782600.6T LT2707003T (lt) 2011-05-12 2012-05-14 Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai

Country Status (14)

Country Link
US (4) US9255068B2 (ja)
EP (2) EP3574908B8 (ja)
JP (5) JP6574572B2 (ja)
CA (1) CA2835876C (ja)
DK (1) DK2707003T3 (ja)
ES (1) ES2739626T3 (ja)
HR (1) HRP20191295T8 (ja)
HU (1) HUE044536T2 (ja)
LT (1) LT2707003T (ja)
PL (1) PL2707003T3 (ja)
PT (1) PT2707003T (ja)
SI (1) SI2707003T1 (ja)
TR (1) TR201911086T4 (ja)
WO (1) WO2012155146A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8856782B2 (en) 2007-03-01 2014-10-07 George Mason Research Foundation, Inc. On-demand disposable virtual work system
US9098698B2 (en) 2008-09-12 2015-08-04 George Mason Research Foundation, Inc. Methods and apparatus for application isolation
EP3574908B8 (en) * 2011-05-12 2024-09-11 Almirall LLC Pharmaceutical composition for oral administration comprising crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2carboxylic acid amide
WO2013082437A1 (en) 2011-12-02 2013-06-06 Invincia, Inc. Methods and apparatus for control and detection of malicious content using a sandbox environment
US20130302442A1 (en) * 2012-05-14 2013-11-14 Paratek Pharmaceuticals, Inc. Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
KR102660864B1 (ko) * 2016-10-19 2024-04-25 테트라페이즈 파마슈티컬스, 인코포레이티드 에라바사이클린의 결정질 형태
JP2020527607A (ja) * 2017-07-21 2020-09-10 アルミラール・リミテッド・ライアビリティ・カンパニーＡｌｍｉｒａｌｌ， Ｌｌｃ 非炎症性病変の処置
CN115380022A (zh) * 2018-04-06 2022-11-22 帕拉特克药品公司 萨瑞环素盐酸盐的制造方法
US20240272239A1 (en) 2021-06-14 2024-08-15 Hioki E.E. Corporation Short circuit detection device and short circuit detection method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (ja) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
EP0599397B1 (en) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US5834450A (en) 1994-02-17 1998-11-10 Pfizer Inc. 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
EP2452935A3 (en) 2006-12-21 2012-08-29 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
CA2892739A1 (en) * 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2009111064A2 (en) * 2008-03-05 2009-09-11 Paratek Pharmaceuticals, Inc. Minocycline compounds and methods of use thereof
TW202332671A (zh) * 2008-05-23 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
EP3574908B8 (en) * 2011-05-12 2024-09-11 Almirall LLC Pharmaceutical composition for oral administration comprising crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2carboxylic acid amide
US20130302442A1 (en) * 2012-05-14 2013-11-14 Paratek Pharmaceuticals, Inc. Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide

Also Published As

Publication number Publication date
JP6574572B2 (ja) 2019-09-11
US20130012480A1 (en) 2013-01-10
EP3574908B8 (en) 2024-09-11
HRP20191295T1 (hr) 2019-10-18
JP2021098695A (ja) 2021-07-01
US20200024223A1 (en) 2020-01-23
SI2707003T1 (sl) 2019-10-30
PL2707003T3 (pl) 2019-11-29
JP2023093519A (ja) 2023-07-04
US9255068B2 (en) 2016-02-09
TR201911086T4 (tr) 2019-08-21
CA2835876A1 (en) 2012-11-15
PT2707003T (pt) 2019-08-05
DK2707003T3 (da) 2019-08-05
JP2017132775A (ja) 2017-08-03
EP2707003A1 (en) 2014-03-19
WO2012155146A1 (en) 2012-11-15
US20160200671A1 (en) 2016-07-14
EP3574908A1 (en) 2019-12-04
EP2707003B1 (en) 2019-05-01
JP2019142867A (ja) 2019-08-29
EP3574908B1 (en) 2024-07-31
ES2739626T3 (es) 2020-02-03
JP6876082B2 (ja) 2021-05-26
HRP20191295T8 (hr) 2020-02-07
JP2014520077A (ja) 2014-08-21
US20190040002A1 (en) 2019-02-07
HUE044536T2 (hu) 2019-10-28
EP2707003A4 (en) 2014-11-12
CA2835876C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
HRP20191295T8 (hr) Kristalne soli amida (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksilne kiseline i postupci uporabe istih
HK1215948A1 (zh) 醯胺及其醫藥用途
SMT201600013B (it) Procedimento per la preparazione di acidi, esteri e ammidi [(3-idrossipiridin-2-carbonil) ammino]alcanoici
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
ZA201307815B (en) N-(1,3,4-oxadiazol-2-yl)arylcarboxamides and use thereof as herbicides
EP2670733A4 (en) HDAC HEMMER AND THERAPY PROCESS THEREFOR
EP2540720A4 (en) 1,3,4,8-TETRAHYDRO-2H-PYRIDO- [1,2-A-] PYRAZINE DERIVATIVE AND USE THEREOF AS HIV INTEGRASE INHIBITORS
HK1163450A1 (zh) 氨基酯類衍生物及其鹽和使用方法
EP2429987A4 (en) AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP2526099A4 (en) IMPROVED METHOD FOR THE MANUFACTURE OF AMID INTERMEDIATE PRODUCTS AND ITS APPLICATION
EP2686688A4 (en) SYSTEMS AND COMPOSITIONS FOR DIAGNOSIS OF BARRETT OSOPHAGES AND METHOD OF USE THEREOF
EP2725010A4 (en) AMID CONNECTION, MANUFACTURING METHOD AND USE
IL220665A0 (en) Pyruvamide compounds as inhibitors of dust time group 1 peptidase allergen and their use
EP2565182A4 (en) NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICAMENT
HK1200815A1 (en) [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors [124]
EP2849757A4 (en) PROCESS FOR USE OF (4S, 4AS, 5AR, 12AS -) - 4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7 - [(METHOXY (METHYL) AMINO) -METHYL] -1,11-DIOXO-1 , 4.4A, 5.5A, 6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
ZA201301799B (en) Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation
EP2682433A4 (en) CARBONYLPROPYLSULFONYLANTHRACENE PYRIDONESULFONIC ACID COMPOUND AND PROCESS FOR PREPARING THE SAME AND USE THEREOF
EP2699560A4 (en) 5-CARBAMOYL-ADAMANTAN-2-YL AMID DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS AND METHOD FOR THE PRODUCTION THEREOF
PL396622A1 (pl) Pochodne diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych, sposób wytwarzania pochodnych diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych oraz zastosowanie pochodnych diestrów 4-metylotiofenylowych kwasów 1-amino-2-metylo-propanofosfonowych
PL392173A1 (pl) Nowy octan R-(-)-2-(5,5-dimetylocykloheks-2-en-1-ylo)etylu i sposób jego otrzymywania
PL392176A1 (pl) Nowe propioniany 2-(5,5-dimetylocykloheks-2-en-1-ylo)etylu i sposób ich otrzymywania
PL392170A1 (pl) Nowy ester etylowy kwasu S-(+)-(5,5-dimetylocykloheks-2-en-1-ylo)octowego i sposób jego otrzymywania
HUP1100239A2 (en) Novel process for the preparation of pharmaceutically active ingredient and the intermediates arose during the process
HUP1100238A2 (en) Novel process for the preparation of pharmaceutically active ingredient and the intermediates arose during the process